BioCentury
ARTICLE | Clinical News

EP-100: Phase I data

June 11, 2012 7:00 AM UTC

An open-label, dose-escalation, U.S. Phase I trial in 38 patients with LHRH-positive solid tumors showed that twice-weekly IV EP-100 for 3 weeks of a 4-week cycle was generally well tolerated and led ...